The Swiss pharma company has reached a “tentative agreement” to settle a class-action lawsuit related to the launch of generic versions of its hypertension drug. The deal has yet to be approved by US judges.
This content was published on
2 minutes
Keystone-SDA/dos
Español
es
Novartis concluye acuerdo extrajudicial en Estados Unidos
The Basel-based multinational told the AWP news agency on Thursday it had agreed to pay $245 million (CHF227 million) to three groups of plaintiffs to fully settle the case.
The antitrust litigation stemmed from a 2011 patent agreement between Novartis and Par, a pharmaceutical subsidiary of US-based Endo International. The two companies were accused of illegally colluding to delay the launch of cheaper generic versions of Novartis’ Exforge, a treatment designed to lower blood pressure and reduce the risk of strokes.
The plaintiffs accused Par of agreeing not to launch an Exforge generic for two years after a patent expired, and Novartis of agreeing not to compete with Par by launching its own generic for 180 days after Par entered the market.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
In its statement, Novartis said the three groups which filed the lawsuit were direct purchasers, indirect purchasers and resellers. The out-of-court settlement, which has yet to be cleared by US judges, “will resolve all outstanding claims related to this matter for Novartis”, the company said.
According to court documents cited by Reuters, annual sales of Exforge in the US were over $400 million before the generic versions were marketed. Reuters also reports that the plaintiffs include major pharmacy chains such as CVS Health, Rite Aid and Walgreens Boots Alliance.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
This content was published on
A committee of Switzerland’s House of Representatives has found the people’s initiative to limit fireworks too extreme, but has suggested a counter-proposal.
UN investigators report evidence of crimes in Syria and call for national dialogue
This content was published on
UN investigators in Geneva report ample evidence of crimes in Syria and urge the regime to follow through on its promise of a national dialogue.
Swiss Trade Union warns EU deal could threaten wages
This content was published on
The Swiss Trade Union Federation warns that the new bilateral agreement between Switzerland and the EU could threaten wage protection and public services.
Credit Suisse fines from Mozambique scandal to fund victims’ compensation
This content was published on
The fines imposed on Credit Suisse for the Mozambique scandal will be allocated to a fund for the victims, amounting to $105.5 million.
‘Confederation is a subsidy machine’: Swiss finance minister
This content was published on
The Swiss government is a machine for distributing subsidies to various actors in the country, says finance minister Karin Keller-Sutter.
Lack of funds ends third bid to salvage Säntis ship from Swiss lake
This content was published on
A third attempt to salvage the steamship Säntis, lying at the bottom of Lake Constance in Switzerland since 1933, has failed before it has even begun.
Nestlé Waters on trial in France over illegal waste dumps
This content was published on
Bottled water producer Nestlé Waters to stand trial, accused of illegally dumping waste and maintaining unauthorised dumps.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Competition authorities probe Novartis over suspected patent abuse
This content was published on
The Swiss competition commission (COMCO) has opened an investigation into suspected unlawful use of a patent by Novartis.
Novartis sets sights on high-value medicines and US market
This content was published on
Swiss pharma giant Novartis has unveiled an updated strategy focused on high-value medicines and boosting its position in the US market.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.